Vesilute
Tissue-specific dipeptide bioregulator (Glu-Asp) that epigenetically normalizes urogenital function through chromatin remodeling, anti-inflammatory cytokine regulation, and smooth muscle tone restoration in the bladder and prostate
Written by Michael Carroll — Owner, Director of Research · Reviewed by the Peptide Initiative Research Team · Editorial standards
Typical dose
1 capsule (10 mg) once daily
Compound profile
Scientific & efficacy data
Hormone Support
Peptide profile
Moderate human trials
Vesilute
1 capsule (10 mg) once daily · Once daily
Molecular formula
C9H14N2O7
- Mol. weight
- 262.2 g/mol
- CAS number
- 3918-84-1
- PubChem
- 99716
- Developed · 1990s (based on urogenital peptide extract research beginning in the 1980s)
- Academic research consortium
Multiple research institutions
Amino acid sequence
Sequence not publicly available or proprietaryBladder Health
Vesilute helps your bladder muscles work better, reducing urgent bathroom trips and improving how much your bladder can comfortably hold.
Prostate Support
This peptide calms inflammation in prostate tissue and helps cells repair themselves, which may ease symptoms of an enlarged prostate.
Tissue Repair
Vesilute turns on repair genes in aging urinary tract cells, helping worn-out tissues heal and work like they did when younger.
Dosing
How much do I take?
1 capsule (10 mg) once daily · once daily before meals
1 capsule (10 mg) once daily
Once daily before meals
Covers all 3 documented dose levels · 2 administration routes · timing · dose-adjustment guidance.
Suitability
Is this right for me?
Best for supporting bladder health and urinary function in aging individuals & bioregulatory approach to benign prostatic hyperplasia (bph) management
Best for
Supporting bladder health and urinary function in aging individuals
Vesilute is particularly well-suited for individuals focused on supporting bladder health and urinary function in aging individuals. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Bioregulatory approach to benign prostatic hyperplasia (BPH) management
Vesilute is particularly well-suited for individuals focused on bioregulatory approach to benign prostatic hyperplasia (bph) management. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Reducing chronic urogenital inflammation through epigenetic mechanisms
Vesilute is particularly well-suited for individuals focused on reducing chronic urogenital inflammation through epigenetic mechanisms. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Complementing standard urological treatments with peptide bioregulator therapy
Vesilute is particularly well-suited for individuals focused on complementing standard urological treatments with peptide bioregulator therapy. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Consider alternatives if
Do not use if
Use with caution if
Not sure?
Compare Vesilute with similar peptides to find the best fit for your goals.
Administration
How do I use it?
Oral (capsule/tablet) · Subcutaneous injection
Route
Vesilute is administered Oral (capsule/tablet)—no injection required
Best sites
Covers reconstitution · step-by-step technique · storage · a sample daily schedule.
Safety
Is it safe?
4 common side effects · 2 serious
Vesilute (fibroin-derived peptide from Bombyx mori silk) demonstrates favorable biocompatibility from cosmetic ingredient testing with minimal allergic or irritant potential despite its animal protein origin.
Limited systemic absorption occurs topically, confining effects to dermal layers with low risk of systemic toxicity. Silk-derived peptides have been used in cosmetics for >20 years without documented serious adverse events in published literature.
Theoretical hypersensitivity risk exists for individuals with silk allergy, though cross-reactivity with purified peptide is low.
Safety information comes from cosmetic ingredient safety testing (INCI approved), manufacturer safety dossiers, and post-market surveillance in over 500 topical formulations globally.
Minimal human clinical trial data exist specifically for efficacy in anti-aging applications, but extensive use in cosmetics establishes acceptable topical safety profile.
Non-systemic bioavailability through skin means serious adverse events are inherently unlikely despite lack of formal drug-level safety studies.
Common side effects · experienced by some users
Mild gastrointestinal discomfort
Slight nausea or stomach upset with oral administration, common with peptide supplements. Usually transient and self-limiting.
Management: Take with a small amount of food or water. Usually resolves within the first few days.
Increased urinary frequency initially
Temporary increase in urination frequency during the first few days as bladder smooth muscle tone normalizes and detrusor function adjusts.
Management: Normal part of the therapeutic process. Should stabilize within 5-7 days as bladder function normalizes.
Mild headache
Transient headache during the adjustment period, potentially related to changes in vascular tone from endothelin-1 normalization.
Management: Ensure adequate hydration. Usually self-limiting within 3-5 days. Standard analgesics may be used if needed.
Minor fatigue
Slight fatigue or drowsiness in the first few days of use as the body adapts to epigenetic changes in gene expression.
Management: Take in the morning. Usually resolves as the body adjusts to the bioregulatory effects.
Less common
These typically resolve with continued use or dose adjustment.
Stop and seek help if
- Severe or worsening side effects that don't improve with dose adjustment or supportive care
- Signs of an allergic reaction—rash, hives, swelling, or difficulty breathing
- Your healthcare provider recommends discontinuation based on your clinical response
- Development of any new medical condition that may be contraindicated with Vesilute
- Pregnancy or planning to become pregnant (unless specifically approved for use during pregnancy)
- Abnormal lab results or clinical markers that suggest adverse effects
Vesilute should only be started, adjusted, or discontinued under medical supervision. This information is for educational purposes only and does not replace professional medical advice. Never stop a prescribed treatment without consulting your healthcare provider first, as abrupt discontinuation may have consequences.
With other peptides
- Safe:Prostamax (Lys-Asp-Gly-Pro tetrapeptide — complementary prostate-specific bioregulator that contains the ED core sequence for synergistic urogenital support) — May be used together under medical guidance.
- Safe:Ventfort (vascular peptide bioregulator — supports microcirculation to urogenital tissues, complementing Vesilute's direct tissue effects) — May be used together under medical guidance.
- Safe:Pinealon (EDR peptide — shares the Glu-Asp core with added arginine; complementary neuroprotective support since urogenital dysfunction often has neurogenic components) — May be used together under medical guidance.
With medications
- Caution:Alpha-1 adrenergic blockers at high doses without monitoring — potential additive effects on smooth muscle relaxation and blood pressure — Use with caution—discuss with your healthcare provider.
- Caution:Anticholinergic medications for overactive bladder without medical guidance — overlapping mechanisms may produce excessive bladder relaxation — Use with caution—discuss with your healthcare provider.
- Caution:Immunosuppressive medications — Vesilute's immunomodulatory effects (cytokine regulation) may interact unpredictably with immunosuppression — Use with caution—discuss with your healthcare provider.
With supplements
- Safe:Multivitamins — Generally safe to take alongside Vesilute. Space doses apart if taking oral formulations to ensure optimal absorption.
- Safe:Electrolyte supplements — Helpful if experiencing any GI side effects that could lead to dehydration. Safe to combine.
Effectiveness
How do I know it's working?
Moderate human trials · first signs days 1-10
Evidence level
Moderate human trials
(Phase 1-2)
Regulatory status
Research compound
Onset of effects
Gradual
(3-4 weeks)
How it works
Vesilute is a mixture of nucleotide and nucleoside compounds derived from cow brain tissue that support cell energy production and repair.
It works by providing the building blocks and energy molecules that cells need to recover from damage, making it useful for treating stroke and traumatic brain injuries. It helps restore normal brain function by improving blood flow and cell metabolism.
The deeper mechanism
Vesilute contains a complex mixture of nucleotides (ATP, GTP, CTP, UTP), nucleosides (adenosine, guanosine, cytidine, uridine), free nucleobases, and nucleotide metabolites derived from bovine brain tissue.
These compounds serve as direct substrates for ATP synthesis through salvage pathway phosphorylation (via nucleoside kinases), bypassing the energy-expensive de novo nucleotide synthesis pathway.
Nucleosides cross the blood-brain barrier via nucleoside transporters (CNT and ENT families), allowing CNS access. Within neurons and glial cells, nucleosides are phosphorylated to nucleotides by deoxynucleotide kinase and nucleoside kinase enzymes, regenerating ATP stores.
The nucleotide/nucleoside components also serve as signaling molecules through P1 (adenosine) and P2 (ATP/ADP) purinergic receptors on neuronal and glial membranes, activating neuroprotective pathways.
Vesilute enhances cerebral blood flow through adenosine receptor-mediated vasodilation and reduces ischemic neuronal damage through P2Y-receptor-dependent suppression of excitotoxic calcium overload.
The preparation also provides direct substrates for DNA/RNA synthesis supporting neuronal plasticity and protein synthesis during recovery phases.
What to expect
Days 1-10
What you might notice
- No dramatic changes initially — epigenetic mechanisms require time for gene expression shifts
- Possible slight increase in urinary frequency as detrusor function begins to normalize
- Mild initial side effects (GI discomfort, headache) that resolve within days
- The peptide-DNA interactions begin immediately but downstream protein changes take days to weeks
What's normal
- Subtle or no noticeable effects during the first week — this is expected with bioregulatory peptides
- Vesilute is working at the epigenetic level: binding DNA, modifying chromatin accessibility, and beginning to alter gene expression patterns
- Anti-inflammatory effects (cytokine reduction) begin building during this period
What's next
- Continue the full 20-30 day treatment course — benefits are cumulative
- Begin tracking urinary symptoms (frequency, urgency, flow quality) for comparison
- Chromatin reactivation and gene expression changes are building toward functional improvements
Week 2-4
What you might notice
- Gradual improvement in urinary function — reduced urgency, improved flow, fewer nighttime awakenings
- Decreased urinary frequency as bladder capacity normalizes
- Reduced discomfort associated with chronic cystitis or prostatitis as inflammation decreases
- Better quality of life related to urogenital function
What's normal
- Pro-inflammatory cytokines (IL-1β, IL-6, TNF-α) are significantly reduced by this point
- Sirtuin-1 upregulation is supporting cellular repair in urogenital tissues
- MMP-9 inhibition and Ki-67/CD98hc enhancement are shifting tissue balance toward regeneration
What's next
- Complete the full course duration (20-30 days)
- Benefits continue to develop after the course ends as epigenetic changes persist
- Plan the next course in 2-6 months to reinforce and extend the bioregulatory effects
Month 1-6 (inter-course period)
What you might notice
- Sustained improvements in urinary function from persistent epigenetic modifications
- Ongoing tissue repair benefits from upregulated regeneration markers
- Benefits may gradually diminish over 3-6 months, indicating readiness for the next treatment course
- Each subsequent course typically builds on and extends the improvements from previous courses
What's normal
- Epigenetic modifications persist beyond the active treatment period — the hallmark of Khavinson bioregulator therapy
- Cyclical treatment every 2-6 months is the standard approach in Russian bioregulator protocols
- Long-term users report cumulative improvements with each treatment course
Signs it's working
Treatment Response
- Improvement in the primary symptoms or condition being treated
- Positive changes in relevant lab values or clinical markers
- Consistent, stable response to Vesilute over time
- Reduction in symptom frequency or severity
General Well-being
- Improved energy levels and daily functioning
- Better quality of life related to the treated condition
- Manageable or absent side effects indicating good tolerance
- Positive feedback from healthcare provider during check-ups
Not seeing results? Common reasons
- Not at therapeutic dose yet—initial doses are for building tolerance, not maximum effect
- Insufficient time at target dose—most compounds need several weeks to show full benefits
- Inconsistent dosing schedule—regular, consistent use is crucial for optimal results
- Individual variation in response—genetics, metabolism, and other factors affect outcomes
- Underlying conditions or medications interfering with absorption or effectiveness
- Improper storage leading to degraded product—always verify proper storage conditions
Key research
Questions
Frequently asked
What is Vesilute and what organ does it target?
Vesilute is a synthetic dipeptide consisting of glutamic acid and aspartic acid (Glu-Asp or ED), developed by Professor Vladimir Khavinson as a tissue-specific bioregulator for the urogenital system. It specifically targets the bladder and prostate, normalizing smooth muscle function, reducing chronic inflammation, and supporting tissue repair. The Glu-Asp sequence was identified as the minimal bioactive unit responsible for the urogenital-specific effects observed with larger peptide extracts from these tissues.
How does a dipeptide of only two amino acids produce significant biological effects?
Despite its minimal size, Vesilute's Glu-Asp dipeptide interacts directly with DNA at specific sequences (GGAG in B-form), altering chromatin accessibility and gene transcription at nanomolar concentrations. This epigenetic mechanism — confirmed by molecular docking studies — allows even the smallest peptide bioregulators to produce tissue-specific effects. Additionally, the ultra-short structure enables efficient cellular uptake via peptide transporters (PepT1), direct nuclear penetration without carrier proteins, and resistance to certain proteases, making it one of the most bioavailable peptide bioregulators in the Khavinson family.
What clinical evidence supports Vesilute for overactive bladder?
A prospective clinical study evaluating Vesilute in 20 women with overactive bladder syndrome demonstrated statistically significant improvements in maximum cystometric capacity, detrusor overactivity parameters, urgency episodes, and micturition frequency using objective urodynamic measurements. Additional clinical trials in Russia have shown benefits for BPH symptom management including improved urinary flow rates and symptom scores. However, these studies were conducted in Russian clinical settings and have not been replicated in Western randomized controlled trials.
How does Vesilute relate to other Khavinson peptides?
Vesilute (ED) shares the Glu-Asp core sequence with several related Khavinson bioregulators: Pinealon (EDR — brain/pineal), Chonluten (EDG — gastrointestinal), and the longer Prostamax (KDGP — prostate). This shared ED core suggests a common DNA-binding mechanism with tissue specificity determined by the additional amino acids. In Khavinson's framework, each organ has an optimal peptide bioregulator, and using complementary peptides in rotation provides comprehensive anti-aging support. Vesilute is often combined with Prostamax for prostate-specific protocols.
Is Vesilute safe for long-term use?
The Khavinson peptide bioregulator class has an extensive safety record spanning over 30 years and 15 million patients across Russia and Eastern Europe, with no reported serious adverse effects. Vesilute's safety profile benefits from its composition of just two naturally occurring amino acids (glutamic acid and aspartic acid), which are readily metabolized through standard amino acid pathways. The standard approach involves cyclical treatment courses (20-30 days) with 2-6 month intervals, rather than continuous daily use. No drug dependence, allergic reactions, or systemic toxicity has been documented.
Can Vesilute replace medications for BPH?
Vesilute should not be considered a replacement for established BPH medications such as alpha-1 blockers (tamsulosin) or 5-alpha-reductase inhibitors (finasteride) without medical guidance. It operates through fundamentally different mechanisms — epigenetic gene regulation versus receptor blockade — and may serve as a complementary approach in conjunction with standard treatments. In Russian clinical practice, peptide bioregulators are often used alongside conventional medications. Individuals with moderate-to-severe BPH should maintain their prescribed treatment plan and discuss any complementary approaches with their urologist.
Further reading
History & related research
History · since 1995
Restoring Bladder and Urogenital System Function Through Peptide Bioregulation
Vesilute is a short synthetic tripeptide bioregulator (Lys-Glu-Asp, or KED sequence) developed by Prof. Vladimir Khavinson at the St.
Read the full history of VesiluteReady for the protocol?
Every dosing tier, administration route, timing note, and dose-adjustment rule for Vesilute, on one page.